The FDA has given its general approval for Arbel Medical to market its IceSense probe, a minimally invasive cryotherapy device for the removal of benign and malignant tumors. The Israel-based company plans to launch the product in 2009 and to seek specific approvals to use the device in removing breast and uterine tumors.

Full Story:
Globes (Israel)

Related Summaries